Wells Fargo | GenomeWeb

Wells Fargo

Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.

In a report issued today, analysts said the company failed to provide "meaningfully improved visibility on broader reimbursement and revenue progression."

The investment bank noted stabilization in Myriad's BRCA1/2 testing franchise, the firm's new management, and its new products. 

The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.